Navigation Links
Onyx Pharmaceuticals Provides Update on Carfilzomib at 53rd American Society of Hematology Annual Meeting
Date:12/10/2011

SOUTH SAN FRANCISCO, Calif., Dec. 10, 2011 /PRNewswire/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA. 

"This expanded data set supports our belief in the potential of carfilzomib to treat late-stage patients with relapsed and refractory multiple myeloma," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals.

Abstract #1877: Multivariate Modeling Reveals Evidence of a Dose-Response Relationship in Phase 2 Studies of Single-Agent Carfilzomib
In an analysis of 430 patients from Phase 2 studies, a highly significant dose-response relationship for carfilzomib was observed across key efficacy endpoints including the primary endpoint of overall response rate (ORR), as well as duration of response (DOR), time to progression (TTP), progression-free survival (PFS) and overall survival (OS). These observations were confirmed and quantified using a statistically rigorous, multivariate analysis. The dose response relationship was also apparent in the magnitude of response (partial response or better) across study participants. While a corresponding dose-toxicity analysis is ongoing, carfilzomib has been shown to have a similar tolerability profile at 20mg/m(2) and 27mg/m(2) doses. These findings are being further assessed in clinical trials evaluating higher dosing regimens.

Abstract #1876: Integrated Safety Data from Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma: An Updated Analysis
In an analysis of 526 patients, the authors con
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Radient Pharmaceuticals Submits an Abstract to the American Society of Colon and Rectal Surgeons
2. Arena Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
3. Webcast Alert: Isis Pharmaceuticals Holds Webcast to Discuss Recent Additions to its Development Pipeline
4. Survival Benefit With Syndax Pharmaceuticals Entinostat Maintained in Women with Advanced Breast Cancer
5. Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™
6. Inovio Pharmaceuticals Closes $4.0 Million Underwritten Financing
7. Onyx Pharmaceuticals to Host a Teleconference to Reprise Key Data From the American Society of Hematology Meeting
8. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
9. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
10. Ampio Pharmaceuticals Announces Agreement to Acquire Key Drug Delivery Technology
11. Radient Pharmaceuticals Two Abstracts Submitted to 2012 Gastrointestinal Cancers Symposium (ASCO) Regarding Onko-Sure® Utility in Colorectal Cancer Are Accepted for Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... second quarter of fiscal year 2015 results on Thursday, January ... A press release with ResMed,s results will be issued after ... a webcast to discuss operating results and future outlook. ... p.m. US Pacific Time and the live webcast of the ...
(Date:12/19/2014)... -- Since last month,s FBI shutdown of online drug ... leading online black market for illegal drugs - Evolution ... of drugs and other illegal items.  New numbers from ... in lowering the numbers of drugs and illegal items ... August. But some new sites that have emerged as ...
(Date:12/19/2014)... LYON, France , Dec. 19, 2014 ... ) and Adocia (Euronext Paris: FR0011184241 – ADOC) today ... ultra-rapid insulin, known as BioChaperone Lispro, for treatment in ... Lispro relies on Adocia,s proprietary BioChaperone® technology and is ... Adocia will develop BioChaperone Lispro with the goal of ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 2Post Silk Road - Another Online Drug Den Now Dominates the DarkNet 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... 5, 2012  Orexigen ® Therapeutics, Inc. (Nasdaq: ... presenting at the 30th Annual J.P. Morgan Healthcare Conference in ... at 9:00 a.m. PST (12:00 p.m. EST). To listen to ... visit the Investor Relations section of the Company,s Web site ...
... , Company expects to meet or exceed ... and earnings declines due to Zyprexa patent expiration. , ... , Company expects to keep 2012 operating expenses essentially flat ... be in the range of $3.10 - $3.20. , ...
Cached Medicine Technology:Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 2Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 3Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 4Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 5
(Date:12/17/2014)... (PRWEB) December 17, 2014 This ... private practices that have made outstanding and innovative ... support and progression of private practice physical therapy ... Physical Therapy Association. , On behalf of Performance ... owner and CEO of Performance accepted the award ...
(Date:12/17/2014)... A group of 127 scientists sent an “open ... to a recent statement by the center that was highly ... the efficacy of all brain exercises. , Signatories to the ... the center’s statement critical of brain exercise companies that overstate ... its case, in a document it had entitled “A Consensus ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
(Date:12/17/2014)... 17, 2014 Project Veritas is releasing ... videos of MIT economist and Obamacare architect Jonathan Gruber ... O’Keefe conducted the interview, which is being distributed on ... was intentional mislabeling in the Affordable Care Act in ... A two-hundred-and-fifty billion dollar per year tax grab. , ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, 2014 (HealthDay ... phenomenon is when an illness that originated in animals jumps ... -- is not uncommon and keeps researchers on their toes ... make inroads into the human population. A new report ... in this case were guinea pigs. More specifically, they were ...
Breaking Medicine News(10 mins):Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3
... May 5 Today marks the launch of the ... network designed to focus exclusively on hospice and palliative ... their families worldwide need palliative care and support each ... cent actually receive it. The need for palliative care ...
... project entitled ,Good Practice in Traditional Chinese Medicine Research ... status of Traditional Chinese Medicine (TCM) research, identify problems ... as well as providing a forum for the exchange ... EU and China. , The three-year project ...
... Increase Hispanic Family Physicians in California LOS ANGELES and ... a $2 million grant to the David Geffen School ... , to expand its International Medical Graduate Program. The ... to serving California,s vulnerable communities and need to pass ...
... (NYSE: BSX ) is scheduled to participate ... Health Care Conference.Jim Tobin, President and Chief Executive Officer, ... beginning at approximately 9:20 a.m. E.T. Following the ... Officer will join Mr. Tobin in a question and ...
... With a Donation, TooNEW YORK, May 5 Honk if you,re ... their wheels trying to think of the perfect Mother,s Day gift, ... to make a unique gift -- one that may save lives ... You can use this traditional time of love and giving to ...
... wary of finding, however , , TUESDAY, May 5 (HealthDay ... the long-sought markers that could discern which tumors are ... , The currently hot debate about the value of ... the fact that the cancer is usually so slow-growing ...
Cached Medicine News:Health News:New International Alliance Launched to Address Urgent Needs of Palliative Care Patients Worldwide 2Health News:King's-led consortium wins €1 million EU funding for Chinese medicine research 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 2Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 3Health News:Kaiser Permanente Grant to Expand UCLA International Medical Center Graduate Program 4Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 2Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 3
... Patients who need punctal occlusion ... eye relief. They also want ... as comfortable and as unobtrusive ... Alcon punctal plugs are growing ...
... delivers the performance and reliability ... management systems. As the industry ... set the benchmark. When it ... performance and technological longevity, Heartlab's ...
Precision near-field imaging combined with the best handling IVUS catheter....
Full Digital Color Ultrasound...
Medicine Products: